Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis

Author:

Lee Chee Khoon12ORCID,Friedlander Michael L.23,Tjokrowidjaja Angelina12,Ledermann Jonathan A.4,Coleman Robert L.5,Mirza Mansoor R.67,Matulonis Ursula A.8,Pujade‐Lauraine Eric910,Bloomfield Ralph11,Goble Sandra12,Wang Ping13,Glasspool Rosalind M.1415,Scott Clare L.216,

Affiliation:

1. National Health and Medical Research Council Clinical Trials Center, University of Sydney Sydney New South Wales Australia

2. Australia New Zealand Gynecological Oncology Group Camperdown New South Wales Australia

3. University of New South Wales Clinical SchoolPrince of Wales Hospital Sydney New South Wales Australia

4. University College London (UCL) Cancer Institute and UCL Hospitals London United Kingdom

5. Department of Gynecologic Oncology and Reproductive Medicine The University of Texas MD Anderson Cancer Center Houston Texas

6. Department of Oncology Rigshospitalet‐Copenhagen University Hospital Copenhagen Denmark

7. Nordic Society of Gynecological Oncology Copenhagen Denmark

8. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts

9. Université Paris Descartes, Assistance Publique–Hôpitaux de Paris Paris France

10. Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO) Paris France

11. AstraZeneca Cambridge United Kingdom

12. Clovis Oncology Boulder Colorado

13. GlaxoSmithKline Waltham Massachusetts

14. Beatson West of Scotland Cancer CenterNational Health Service Greater Glasgow and Clyde and University of Glasgow Glasgow United Kingdom

15. Scottish Gynecological Cancer Trials Group University of Glasgow Glasgow United Kingdom

16. Walter and Eliza Hall Institute of Medical Research, Stem Cells, and Cancer, University of Melbourne Melbourne Victoria Australia

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3